FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine.
EFFECT: invention discloses the possibility of carrying out a combination therapy of various oncological diseases using the WNT5A peptide or its formylated derivative in combination with one or more checkpoint inhibitors.
12 cl, 6 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2798348C2 |
| COMBINATION | 2015 |
|
RU2744841C2 |
| MYL9 ANTIBODY | 2017 |
|
RU2741802C2 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
